Complete response in patient with liver metastasis of HER2-positive breast cancer following therapy with margetuximab: a case report

被引:1
|
作者
Chang, Haiyan [1 ]
Hu, Ting [1 ]
Hu, Jie [1 ]
Ding, Teng [2 ]
Wang, Qiong [1 ,3 ]
Cheng, Jing [1 ]
机构
[1] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Oncol, Wuhan, Peoples R China
[2] Zai Lab Shanghai Co Ltd, Med Affairs Dept, Shanghai, Peoples R China
[3] Huazhong Univ Sci & Technol, Dept Oncol, Union Hosp, Tongji Med Coll, 109 Machang Rd, Wuhan, Hubei, Peoples R China
关键词
breast cancer; human epidermal growth factor receptor 2; liver metastasis; margetuximab; TRASTUZUMAB; POLYMORPHISMS; BENEFIT;
D O I
10.1097/CAD.0000000000001466
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Metastatic human epidermal growth factor receptor 2 (HER2) positive breast cancer has a poor prognosis and few effective targeted therapies. However, several anti-HER2 agents are emerging in conjunction with chemotherapy, which may lead to increased rates of pathological complete response in patients with HER2-positive metastatic breast cancer. Among them, margetuximab demonstrated a significant improvement in progression-free survival compared with trastuzumab, when combined with chemotherapy in pretreated patients. Here we present a case of a 67-year-old female patient who was diagnosed with HER2-positive, histological grade III and invasive ductal carcinoma of the left breast in September 2018. She received postoperative adjuvant therapy with EC-TH plus radiotherapy, followed by therapy with HER2-targeted trastuzumab for 1 year (till December 2019). In May 2020, routine reexamination showed a supraclavicular lymph node and bone metastasis. Patient was then treated with pyrotinib, capecitabine and bisphosphonate for a period of 3 months. In December 2020, liver MRI revealed multiple liver metastases. The patient received eight cycles of second-line therapy (vinorelbine plus margetuximab) from January 2021. Since the ninth cycle, the patient was continued with only margetuximab. In March 2021, MRI showed a 70% decrease in the liver metastasis lesions. By June 2021, liver lesions were totally disappeared. During therapy, patient experienced only grade-1 anemia. This case demonstrates that margetuximab plus chemotherapy is safe and might bring clinical benefits for patients with HER2-positive breast cancer with liver metastasis. Further studies evaluating the efficacy and safety of margetuximab in Chinese HER2-positive breast cancer patients are needed.
引用
收藏
页码:883 / 887
页数:5
相关论文
共 50 条
  • [41] Outcomes following adjuvant therapy for HER2-positive early breast cancer in the elderly
    Otter, Sophie
    Ring, Alistair
    EXPERT REVIEW OF ANTICANCER THERAPY, 2010, 10 (08) : 1265 - 1272
  • [42] Pathological complete response and survival of HER2-positive invasive breast cancer following docetaxel, carboplatin, and trastuzumab neoadjuvant therapy: a Vietnamese experience
    Le, Duc Thanh
    Do, Tu Anh
    Bui, Lap Thanh
    Do, Kien Hung
    Nguyen, Chu Van
    ONCOLOGY IN CLINICAL PRACTICE, 2023, 19 (04): : 235 - 243
  • [43] Solitary pituitary metastasis from HER2-positive breast cancer
    Kam, Jeremy
    Kam, Jeffrey
    Mann, G. Bruce
    Phillips, Claire
    Wentworth, John M.
    King, James
    Lindeman, Geoffrey J.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2017, 13 (02) : E181 - E184
  • [44] Refining therapy in patients with HER2-positive Breast cancer with Central Nervous System metastasis
    Batista, Marta Filipa Freire Vaz
    Eiriz, Ines
    Fitzpatrick, Amanda
    Le Du, Fanny
    Braga, Sofia
    Costa, Diogo Alpuim
    BREAST CARE, 2022, 17 (06) : 524 - 532
  • [45] FDA Approval Summary: Margetuximab plus Chemotherapy for Advanced or Metastatic HER2-Positive Breast Cancer
    Royce, Melanie
    Osgood, Christy L.
    Amatya, Anup K.
    Fiero, Mallorie H.
    Chang, C. J. George
    Ricks, Tiffany K.
    Shetty, Krithika A.
    Kraft, Jeffrey
    Qiu, Junshan
    Song, Pengfei
    Charlab, Rosane
    Yu, Jingyu
    King, Kathryn E.
    Rastogi, Anshu
    Janelsins, Brian
    Weinberg, Wendy C.
    Clouse, Kathleen
    Borders-Hemphill, Vicky
    Brown, Lindsey
    Gomez-Broughton, Candace
    Li, Zhong
    Thuy Thanh Nguyen
    Qiu, Zhihao
    Anh-Thy Ly
    Chang, Suyoung
    Gao, Tingting
    Tu, Chi-Ming
    King-Kallimanis, Bellinda
    Pierce, William F.
    Chiang, Kelly
    Lee, Clara
    Goldberg, Kirsten B.
    Leighton, John K.
    Tang, Shenghui
    Pazdur, Richard
    Beaver, Julia A.
    Amiri-Kordestani, Laleh
    CLINICAL CANCER RESEARCH, 2022, 28 (08) : 1487 - 1492
  • [46] HER2-positive breast cancer
    Loibl, Sibylle
    Gianni, Luca
    LANCET, 2017, 389 (10087): : 2415 - 2429
  • [47] Therapy for HER2-Positive Metastatic Breast Cancer REPLY
    Winer, Eric P.
    NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (25):
  • [48] Targeted therapy in HER2-positive breast cancer (Review)
    Li, Shu Guang
    Li, Li
    BIOMEDICAL REPORTS, 2013, 1 (04) : 499 - 505
  • [50] Adjuvant trastuzurnab therapy for HER2-Positive breast cancer
    Jahanzeb, Mohammad
    CLINICAL BREAST CANCER, 2008, 8 (04) : 324 - 333